Usefulness of the implantable cardiodefibrillator (icd) in the prevention of sudden death. Results of evidence based medicine

Celso Mendoza González

2007, Number S2

<< Back Next >>

Arch Cardiol Mex 2007; 77 (S2)

Usefulness of the implantable cardiodefibrillator (icd) in the prevention of sudden death. Results of evidence based medicine

Mendoza GC

Full text

How to cite this article

Language: Spanish
References: 10
Page: 44-46
PDF size: 68.27 Kb.

ABSTRACT

A great percentage of patients who have suffered a myocardial infarction have ventricular left dysfunction. In agreement with the different prospective studies, many of these patients will have an event of ventricular arrhythmias that does them candidates for receiving a strategy of primary or secondary prevention with an ICD. The same studies have showed a significant reduction in mortality with the therapy of the ICD compared with the conventional therapy what demonstrates the balance cost - benefit in favor of the use of these devices in long periods of follow-up.
The benefits of mortality with the use of the therapy with ICD at the primary prevention are at least so good as those of the secondary prevention of agreement to the results of different prospective studies.

REFERENCES

Bigger JT, Fleiss JL, Kleiger R, et al: The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984; 69: 250-258.
Hohnsloser SH, Klingenheben T, Zabel M, et al: Prevalence, characteristics and prognostic value during long-term follow-up of NSVT after MI in the thromboloytic era. J Am Coll Cardiol 1999; 1895-1902.
Hallstrom A, P.C., Greene HL, Huther M, et al: Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac arrhythmia Suppression Trial. J Am Coll Cardiol 1995; 25(6): 1250-1257.
Copie X, H.K., Staunton A, Fei L, et al: Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a two-year follow-up study. J Am Coll Cardiol 1996. 27(2): 270-276.
The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329 (22):1615.
Rouleau JL, Talajic M, Sussex B, et al: Myocardial Infarction Patients in the 1990s-Their Risk factors, Stratification and Survival in Canada: The Canadian Assessment of Myocardial Infarction (CAMI) Study. J Am Coll Cardiol 1996; 27: 1119-1127.
Buxton AE, Lee KL, DiCarlo L, et al: Nonsustained ventricular tachycardia in coronary artery disease: relation to inducible sustained ventricular tachycardia. Ann Intern Med. 1996; 125: 35-39.
Every NR, Hlatky MA, McDonald KM, et al: Estimating the proportion of post-myocardial infarction patients who may benefit from prophylactic implantable defibrillator placement from analysis of the CAST registry. Am J Cardiol. 1998; 82(5): 683-685.
Grönefeld G, Connolly SJ, Hohnloser SH: The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): Rationale, Design and Specific Aims. Card Electrophysiol Rev 2003; 7: 447-451.
Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351(24): 2481-8.